RapidAI Receives FDA Clearance for Pulmonary Embolism Software

RapidAI has received the FDA’s 510(k) clearance for its Rapid PE Triage & Notification artificial intelligence (AI) software for fast identification and communication of suspected central pulmonary embolism.

Used in conjunction with RapidAI’s Rapid Workflow for PE, the software is intended to manage patient care from the moment a pulmonary embolism is suspected to diagnosis and through treatment.

By automatically identifying a suspected pulmonary embolism and delivering real-time notifications to physicians, the software is meant to help triage patients faster and put together care teams more quickly, reducing the overall time to treatment, the company said.

San Mateo, Calif.-based RapidAI specializes in neurovascular and vascular AI-enhanced clinical decision support and patient workflow software.